April 21 (Mainichi Newspaper) and April 24 (Nikkei
Newspaper)
大村氏のイベルメクチン、新型コロナに効果 (米ユタ大が報告)
English Summary:
According to a recent report from Utah University
in US, Nobel-winning anti-parasites « Ivermectin » (sold by MERCK) was found to reduce
the death rate of COVID-19 patients (over 700 ) by 6 times (from 8.5% to 1.4 %) world wide. Its "single" dose (O.15 mg/kg) appears
to be basically same as that for patients suffering from pathogenic insects in
the past. The clinical data are based on Ivermectin trials in North America,
Europe and Asia (at 169 hospitals) during January-March this year. In severe
cases requiring ventilators (oxygen suppliers) at ICU (intense care unit), the
death rate of Ivermectin-treated patients is only 7%, while that of non-treated
(or treated with other drugs) is 21%.
Scientific Note :
How can Ivermectin block the COVID-19 infection ? In general the infection of RNA viruses such as influenza, HIV and COVID-19 requires the major « pathogenic » kinase PAK1 in hosts. More than a decades ago, we found that this drug blocks PAK1 in cancer cells, suppressing their growth with IC50 around 2.5 micro M, but without any effect on normal cell growth (1). More recently a team at Monash University in Melbourne found that this drug in fact inhibits the COVID-19 infection in Vero cells with IC50 around 2.5 micro M (2). Furthermore, there are a few scientific evidences indicating that the pathogenic process of this virus, in particular « fibrosis » (inflammation of lungs) which causes the death, also depends on PAK1 (3). In addition PAK1-blockers in general stimulate our immune system, producing an antibody against pathogenic bacteria or viruses (3). Thus, "single stone kills more than two birds"!
Finally I located the original "English" source of this news/finding:
Scientific Note :
How can Ivermectin block the COVID-19 infection ? In general the infection of RNA viruses such as influenza, HIV and COVID-19 requires the major « pathogenic » kinase PAK1 in hosts. More than a decades ago, we found that this drug blocks PAK1 in cancer cells, suppressing their growth with IC50 around 2.5 micro M, but without any effect on normal cell growth (1). More recently a team at Monash University in Melbourne found that this drug in fact inhibits the COVID-19 infection in Vero cells with IC50 around 2.5 micro M (2). Furthermore, there are a few scientific evidences indicating that the pathogenic process of this virus, in particular « fibrosis » (inflammation of lungs) which causes the death, also depends on PAK1 (3). In addition PAK1-blockers in general stimulate our immune system, producing an antibody against pathogenic bacteria or viruses (3). Thus, "single stone kills more than two birds"!
Finally I located the original "English" source of this news/finding:
Usefulness of Ivermectin in COVID-19 Illness
Amit
Patel (April 19, 2020)
Abstract
Importance:
There is no established anti-viral therapy for treating COVID-19 illness.
Objective:
To study the usefulness of Ivermectin, an antimicrobial therapy, in COVID-19
outcomes.
Design:
An international, multicenter, observational propensity-score matched
case-controlled study using prospectively collected data on patients diagnosed
with COVID-19 between January 1, 2020 and March 31, 2020.
Setting:
An international multi- institutional deidentified healthcare outcomes
database.
Participants:
Hospitalized patients diagnosed with COVID-19 determined by presence of a
positive laboratory finding confirming SARS-CoV-2 infection.
Exposure:
Ivermectin (O.15 mg/Kg) administered "once" compared with COVID-19 patients receiving
medical therapy without ivermectin.
Results:
The cohort (including 704 ivermectin treated and 704 controls) was derived from
169 hospitals across 3 continents with COVID-19 illness. The patients were
matched for age, sex, race or ethnicity, comorbidities and a illness severity
score (qSOFA). Of those requiring mechanical ventilation fewer patients died in
the ivermectin group (7.3% versus 21.3%) and overall death rates were lower
with ivermectin (1.4% versus 8.5%; HR 0.20 CI 95% 0.11-0.37, p<0.0001).
0 件のコメント:
コメントを投稿